Your browser doesn't support javascript.
loading
EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis.
Agache, Ioana; Akdis, Cezmi A; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; Del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez-Arnau, Ana; Gutermuth, Jan; Guttman-Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y; O'Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek.
Afiliación
  • Agache I; Faculty of Medicine, Transylvania University, Brasov, Romania.
  • Akdis CA; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Akdis M; Christine-Kühne-Center for Allergy Research and Education (CK-CARE, Davos, Switzerland.
  • Brockow K; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Chivato T; Department of Dermatology and Allergology Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
  • Del Giacco S; School of Medicine, University CEU San Pablo, Madrid, Spain.
  • Eiwegger T; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Eyerich K; Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
  • Giménez-Arnau A; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Gutermuth J; Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, Departments of Paediatrics and Immunology, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
  • Guttman-Yassky E; Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.
  • Maurer M; Department of Dermatology, Hospital del Mar- Institut Mar d'InvestigacionsMèdiques, UniversitatAutònoma de Barcelona, Barcelona, Spain.
  • Ogg G; Department of Dermatology, VrijeUniversiteit Brussel (VUB), UniversitairZiekenhuis Brussel, Brussels, Belgium.
  • Ong PY; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • O'Mahony L; Dermatological Allergology, Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schwarze J; MRC Human Immunology Unit, Radcliffe Department of Medicine, MRC Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Warner A; Division of Clinical Immunology & Allergy, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Werfel T; Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Palomares O; Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
  • Jutel M; Allergy UK, Kent, UK.
Allergy ; 76(4): 988-1009, 2021 04.
Article en En | MEDLINE | ID: mdl-33538044
ABSTRACT
Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Dermatitis Atópica / Eccema Tipo de estudio: Guideline Límite: Adult / Child / Humans Idioma: En Revista: Allergy Año: 2021 Tipo del documento: Article País de afiliación: Rumanía
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Dermatitis Atópica / Eccema Tipo de estudio: Guideline Límite: Adult / Child / Humans Idioma: En Revista: Allergy Año: 2021 Tipo del documento: Article País de afiliación: Rumanía